Evidence map›Paper›PMID 40256341›Full record

ArticleThe Journal of clinical and aesthetic dermatology2025

A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of 10% Aminolevulinic Acid Gel in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp with Red Light Photodynamic Therapy.

Joel L Cohen, John H Tu, Megan P Couvillion, S Sasha Jazayeri, Nathalie C Zeitouni, Sherrif F Ibrahim, Edward L Lain, C William Hanke, Corinna Zogel, Beate Schmitz and 2 more

Abstract read
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joel L CohenDr. Cohen is with AboutSkin Research in Greenwood Village, Colorado.
John H TuDr. Tu is with Skin Search of Rochester in Rochester, New York.
Megan P CouvillionDr. Couvillion is with the Austin Institute for Clinical Research in Houston, Texas.
S Sasha JazayeriDr. Jazayeri is with Alliance Dermatology and Mohs Center in Phoenix, Arizona.
Nathalie C ZeitouniDr. Zeitouni is with Medical Dermatology Specialists Phoenix in Phoenix, Arizona.
Sherrif F IbrahimDr. Ibrahim is with Rochester Dermatologic Surgery in Victor, New York.
Edward L LainDr. Lain is with the Austin Institute for Clinical Research in Pflugerville, Texas.
C William HankeDr. Hanke is with Laser and Skin Surgery Center of Indiana in Indianapolis, Indiana.
Corinna ZogelDrs. Zogel, Schmitz, and Zeuner are with Biofrontera Discovery GmbH in Leverkusen, Germany.
Beate SchmitzDrs. Zogel, Schmitz, and Zeuner are with Biofrontera Discovery GmbH in Leverkusen, Germany.
Marie-Theres ZeunerDrs. Zogel, Schmitz, and Zeuner are with Biofrontera Discovery GmbH in Leverkusen, Germany.
Todd SchlesingerDr. Schlesinger is with the Clinical Research Center of the Carolinas in Charleston, South Carolina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Dermatologists regularly encounter patients having expanded fields with numerous actinic keratosis (AK) lesions on the face and scalp. Field-directed red light photodynamic therapy (PDT) is a well-established treatment, yet published data on the safety of PDT on large areas is scarce. We aimed to evaluate the safety and tolerability of red light PDT in treating expanded AK fields on the face and scalp. Methods: This was a non-randomized, open-label, multicenter study. After lesion preparation, 6g of 10% aminolevulinic acid (ALA) gel were applied to the treatment field (60 cm Results: All participants (n=100) had adverse reactions. No previously unknown effects, serious adverse events, or deaths were reported. The most frequent application site reactions were pain/burning (96.0%), exfoliation (87.0%), and erythema (86.0%). Most treatment-emergent adverse events were of mild to moderate severity and lasted slightly longer compared to those experienced after treatment of smaller areas. The mean maximum pain during PDT was 7.4±2.1 on an 11-point numeric rating scale. A transient increase in blood pressure on the day that PDT was performed was not clinically significant. Limitations: Although the allowed use of pain-reducing measures might have influenced evaluation of pain, it reflects how the procedure is managed in current practice. Concklusion: PDT with 10% ALA gel and red light illumination on an expanded treatment field was generally well tolerated.

Indexed as

10% ALA gelactinic keratosesactinic keratosisaminolevulinic acidBF-200 ALAclinical researchPhotodynamic therapyred lightRhodoLEDsafety

Identifiers

PMID40256341
PMCPMC12007652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.